{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:59:53Z","timestamp":1790503193947,"version":"4.1.0"},"reference-count":59,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T00:00:00Z","timestamp":1499472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Epithelial ovarian cancer is a fatal disease, with a cure rate of only 30%. Several recent studies have targeted integrins for cancer treatment. Preclinical studies have shown the effectiveness of several integrin inhibitors for blocking cancer progression, especially by blocking angiogenesis. Because the initial critical step in ovarian cancer metastasis is the attachment of cancer cells to the peritoneum or omentum and because clinical trials have provided positive results for anti-angiogenic therapy, therapies targeting integrins may be the most feasible approach for treating cancer. This review summarizes the current understanding of integrin biology in ovarian cancer metastasis and various therapeutic approaches involving integrin inhibitors. However, no integrin inhibitor has shown favorable results thus far. However, conjugates of cytotoxic agents with the triplet sequence arginine-glycine-aspartate (RGD) peptides targeting \u03b15\u03b21-, \u03b1v\u03b23-, and \u03b1v\u03b26-integrins may be promising integrin-targeting therapies for further clinical investigation.<\/jats:p>","DOI":"10.3390\/cancers9070083","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T11:05:31Z","timestamp":1499684731000},"page":"83","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review"],"prefix":"10.3390","volume":"9","author":[{"given":"Masaki","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka Suita, Osaka 5650871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka Suita, Osaka 5650871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka Suita, Osaka 5650871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canlet.2011.05.022","article-title":"Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells","volume":"309","author":"Cohen","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_3","first-page":"1","article-title":"Molecular targeted drug therapy of ovarian cancer","volume":"1","author":"Fan","year":"2016","journal-title":"ARC J. Gynecol. Obstet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1172\/JCI74778","article-title":"Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion","volume":"124","author":"Kenny","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/gyno.1999.5388","article-title":"\u03b21-Integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro","volume":"73","author":"Thomas","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4161\/cam.18702","article-title":"The regulation of integrin function by divalent cations","volume":"6","author":"Zhang","year":"2012","journal-title":"Cell Adh. Migr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: Bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: Biological implications and therapeutic opportunities","volume":"10","author":"Jay","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","article-title":"A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer","volume":"34","author":"Oronsky","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3802\/jgo.2010.21.2.75","article-title":"Maximal cytoreductive effort in epithelial ovarian cancer surgery","volume":"21","author":"Shih","year":"2010","journal-title":"J. Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_15","unstructured":"National Comprehensive Cancer Network (2017, June 19). NCCN Clinical Practice Guidelines in Oncology. Available online: https:\/\/www.nccn.org."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1517\/14656566.8.14.2293","article-title":"Recurrent epithelial ovarian cancer: Pharmacotherapy and novel therapeutics","volume":"8","author":"Modesitt","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","article-title":"Role of vascular endothelial growth factor in regulation of physiological angiogenesis","volume":"280","author":"Ferrara","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Eric","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"2260","article-title":"The promise of antiangiogenic therapy for ovarian cancer","volume":"23","author":"Jazaeri","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","article-title":"Loss of E-cadherin promotes ovarian cancer metastasis via \u03b15-integrin, which is a therapeutic target","volume":"68","author":"Sawada","year":"2008","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0002-9440(10)63058-1","article-title":"\u03b21-Integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids","volume":"159","author":"Casey","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15588","DOI":"10.3390\/ijms131215588","article-title":"Elevated levels of Lewis y and integrin \u03b15\u03b21 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma","volume":"13","author":"Hu","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/labinvest.2015.82","article-title":"Clinical significance of the integrin \u03b16\u03b24 in human malignancies","volume":"95","author":"Stewart","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.prp.2015.10.002","article-title":"Integrins and haptoglobin: Molecules overexpressed in ovarian cancer","volume":"211","author":"David","year":"2015","journal-title":"Pathol. Res. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61\u201370.","DOI":"10.1038\/nature11412"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1083\/jcb.111.6.2795","article-title":"The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin","volume":"111","author":"Charo","year":"1990","journal-title":"J. Cell Biol."},{"key":"ref_31","first-page":"2724","article-title":"Integrin \u03b1v\u03b23 promotes M21 melanoma growth in human skin by regulating tumor cell survival","volume":"59","author":"Petitclerc","year":"1999","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1172\/JCI118227","article-title":"Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin","volume":"96","author":"Brooks","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1593\/neo.08740","article-title":"Tumor-selective response to antibody-mediated targeting of \u03b1v\u03b23 integrin in ovarian cancer","volume":"10","author":"Landen","year":"2008","journal-title":"Neoplasia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0090-8258(03)00321-4","article-title":"\u03b1V- and \u03b21-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients","volume":"90","author":"Davidson","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-9966-32-36","article-title":"Expression of Lewis y antigen and integrin \u03b1v, \u03b23 in ovarian cancer and their relationship with chemotherapeutic drug resistance","volume":"32","author":"Gao","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.2353\/ajpath.2009.090028","article-title":"\u03b23-Integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer","volume":"175","author":"Kaur","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_37","first-page":"336","article-title":"VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer","volume":"5","author":"Huang","year":"2013","journal-title":"Am. J. Transl. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2013.12.031","article-title":"Inhibition of \u03b14\u03b21 integrin increases ovarian cancer response to carboplatin","volume":"132","author":"Scalici","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1158\/0008-5472.CAN-08-2678","article-title":"Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis","volume":"69","author":"Atkins","year":"2009","journal-title":"Cancer Res."},{"key":"ref_40","first-page":"273","article-title":"Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent","volume":"5","author":"Ramakrishnan","year":"2006","journal-title":"J. Exp. Ther. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1517\/14712598.2012.646985","article-title":"Volociximab in cancer","volume":"12","author":"Almokadem","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/onc.2010.532","article-title":"Ligand independent activation of c-Met by fibronectin and \u03b15\u03b21-integrin regulates ovarian cancer invasion and metastasis","volume":"30","author":"Mitra","year":"2011","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","article-title":"Volociximab, a chimeric monoclonal antibody that specifically binds \u03b15\u03b21 integrin: A phase I, pharmacokinetic, and biological correlative study","volume":"14","author":"Ricart","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","article-title":"A phase II, single-arm study of the anti-\u03b15\u03b21 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer","volume":"121","author":"Matthews","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.3892\/mmr.2015.4443","article-title":"Inhibition of integrin \u03b21 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK\/STAT1 signaling pathway","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1242\/dev.119.4.1093","article-title":"Embryonic mesodermal defects in \u03b15 integrin-deficient mice","volume":"119","author":"Yang","year":"1993","journal-title":"Development"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mehy.2014.11.018","article-title":"The specifical inhibition of the expression of integrin alpha5\/beta1 probably enhances the treatment effects and improves the prognosis of epithelial ovarian cancer","volume":"84","author":"Xie","year":"2015","journal-title":"Med. Hypotheses"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cas.13228","article-title":"Recent advances in genetic modification of adenovirus vectors for cancer treatment","volume":"108","author":"Yamamoto","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bjc.2011.183","article-title":"A randomised, phase II study of intetumumab, an anti-\u03b1v-integrin mAb, alone and with dacarbazine in stage IV melanoma","volume":"105","author":"Pavlick","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-06-2779","article-title":"Phase I evaluation of a fully human anti-alpha v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors","volume":"13","author":"Mullamitha","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10637-007-9077-0","article-title":"Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors","volume":"26","author":"Delbaldo","year":"2008","journal-title":"Invest. New Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cncr.24821","article-title":"A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin\u03b1v\u03b23, \u00b1dacarbazine in patients with stage IV metastatic melanoma","volume":"116","author":"Hersey","year":"2010","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-011-0650-1","article-title":"Cilengitide in patients with recurrent glioblastoma: The results of NABTC 03-02, a phase II trial with measures of treatment delivery","volume":"106","author":"Gilbert","year":"2012","journal-title":"J. Neurooncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1002\/cncr.27585","article-title":"A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma","volume":"118","author":"Nabors","year":"2012","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1021\/acs.jmedchem.6b01711","article-title":"Emergence of small-molecule non-RGD-mimetic inhibitors for RGD integrins","volume":"60","author":"Miller","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1021\/mp3002733","article-title":"RGD-based strategies to target \u03b1v\u03b23 integrin in cancer therapy and diagnosis","volume":"9","author":"Danhier","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2009.08.011","article-title":"Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel","volume":"140","author":"Danhier","year":"2009","journal-title":"J. Control. Release"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s12032-010-9621-1","article-title":"Integrin-targeted paclitaxel nanoliposomes for tumor therapy","volume":"28","author":"Meng","year":"2011","journal-title":"Med. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/9\/7\/83\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:42:00Z","timestamp":1760208120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/9\/7\/83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,8]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["cancers9070083"],"URL":"https:\/\/doi.org\/10.3390\/cancers9070083","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,8]]}}}